EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Universal Strategy of Anti‐Tumor mRNA Vaccine by Harnessing “Off‐the‐Shelf” Immunity

Jiayan Fu, Shuangqi Wu, Nengcheng Bao, Lili Wu, Huiru Qu, Zhechao Wang, Haiyang Dong, Jian Wu, Yongfeng Jin iD

Advanced Science · 2025-02 · 12 (8)

DOI: 10.1002/advs.202401287 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 06.01.2025. Verfasst von Jiayan Fu und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, Zhejiang, 310058, China. Hauptthemen laut MEDLINE: Cancer Vaccines, mRNA Vaccines, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Starry Night Science Fund at Shanghai Institute for Advanced Study of Zhejiang University, Department of Science and Technology of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Personalized neoantigen cancer mRNA vaccines are promising candidates for precision medicine. However, the difficulty of identifying neoantigens heavily hinders their broad applicability. This study developed a universal strategy of anti‐tumor mRNA vaccine by harnessing “off‐the‐shelf” immunity to known antigens. First, the model antigen ovalbumin (OVA) is used for mRNA vaccine design. In vitro test indicated that this mRNA vaccine reprogrammed tumor cells that can be recognized and killed by OVA‐specific cytotoxic T lymphocytes (CTLs). In situ mRNA vaccine notably inhibited tumor growth across three subcutaneous solid tumor models in mice. Further single‐cell sequencing analyses revealed that mRNA vaccination act to reshape the immunosuppressive tumor microenvironment (TME) toward more proinflammatory characteristics. Strikingly, this framework of mRNA‐based strategy can be applied to two clinical pathogen antigens, hepatitis B surface antigen (HBsAg), and SARS‐CoV‐2 spike receptor‐binding domain (SRBD). Interestingly, the mRNA‐based strategy largely recapitulated the scenario of spontaneous cancer regression following pathogen infection or vaccination. Collectively, this study provides not only proof of concept for universal anti‐tumor mRNA therapy, but also mechanistic insights in echoing the long‐standing puzzle of spontaneous cancer regression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesmRNA VaccinesNeoplasmsAnimalsMiceHumansTumor MicroenvironmentT-Lymphocytes, CytotoxicSARS-CoV-2OvalbuminRNA, MessengerCOVID-19Spike Glycoprotein, CoronavirusAntigens, NeoplasmVaccines, SyntheticFemaleCell Line, TumorMice, Inbred C57BL

Stichwörter der Autor:innen

anti‐tumormRNA vaccineproof of conceptspontaneous cancer regressionuniversal strategy

Substanzen

Cancer VaccinesmRNA VaccinesOvalbuminRNA, MessengerSpike Glycoprotein, CoronavirusAntigens, NeoplasmVaccines, Syntheticspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, Zhejiang, 310058, China.
  • MOE Laboratory of Biosystems Homeostasis & Protection, Innovation Center for Cell Signaling Network, College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang, 310058, China.
  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310006, China.

ORCID-Profile: Yongfeng Jin

Förderung

  • National Key Research and Development Program of China
  • Starry Night Science Fund at Shanghai Institute for Advanced Study of Zhejiang University
  • Department of Science and Technology of Zhejiang Province
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Fu, J., Wu, S., Bao, N., Wu, L., Qu, H., Wang, Z., Dong, H., Wu, J., & Jin, Y. (2025). A Universal Strategy of Anti‐Tumor mRNA Vaccine by Harnessing “Off‐the‐Shelf” Immunity. Advanced Science, 12(8). https://doi.org/10.1002/advs.202401287

Vancouver

Fu J, Wu S, Bao N, Wu L, Qu H, Wang Z, et al. A Universal Strategy of Anti‐Tumor mRNA Vaccine by Harnessing “Off‐the‐Shelf” Immunity. Advanced Science. 2025;12(8). doi:10.1002/advs.202401287

BibTeX
@article{Fu2025,
  author = {Fu, Jiayan and Wu, Shuangqi and Bao, Nengcheng and Wu, Lili and Qu, Huiru and Wang, Zhechao and Dong, Haiyang and Wu, Jian and Jin, Yongfeng},
  title = {A Universal Strategy of Anti‐Tumor mRNA Vaccine by Harnessing “Off‐the‐Shelf” Immunity},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {8},
  doi = {10.1002/advs.202401287}
}
Kostenlos starten →